TriSalus Life Sciences Partners with Geo-Med to Improve Liver Cancer Treatment for Veterans

TriSalus Life Sciences Partners with Geo-Med to Enhance Treatment for Veterans with Liver Cancer

TriSalus Life Sciences Inc. (Nasdaq: TLSI), an innovative oncology company, announces a strategic partnership with Geo-Med, LLC, aimed at improving treatment access for veterans diagnosed with hepatocellular carcinoma (HCC). This collaboration focuses on making the TriNav Infusion System more widely available in U.S. Department of Veterans Affairs (VA) medical centers. HCC, the most common form of liver cancer, disproportionately affects veterans, making this partnership particularly significant. By leveraging TriSalus's proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology, the TriNav system allows for targeted drug delivery directly to tumors while reducing the risk of off-target effects, ultimately enhancing treatment efficacy.

The partnership emphasizes TriSalus’s commitment to improving outcomes for liver cancer patients, especially within the veteran population. Mary Szela, CEO of TriSalus, underscores the importance of this collaboration as a vital step toward expanding access to innovative treatment options. With the expertise of Geo-Med in procurement for the VA and U.S. Department of Defense (DoD), the partnership ensures that veterans can receive necessary interventions in a timely manner. The focus on veterans aligns with TriSalus's mission, as they aim to address significant health disparities faced by those who have served in the military.

In addition to enhancing access to the TriNav Infusion System, the partnership aims to tackle the anatomical complexities associated with traditional infusion methods. The TriNav system, alongside other FDA-cleared devices from TriSalus, utilizes PEDD to deliver therapeutics effectively, not just for liver cancer but also for pancreatic tumors. Mike Locke, CEO of Geo-Med, expresses pride in working with TriSalus to bring advanced medical technology to veterans battling aggressive forms of cancer, reinforcing the shared goal of improving patient quality of life.

In related news, TriSalus’s initiative represents a broader trend in oncology, where innovative drug delivery systems are increasingly recognized for their potential to revolutionize treatment paradigms. This partnership not only addresses immediate healthcare needs but also sets a precedent for future collaborations aimed at improving cancer care for underserved populations. The alignment of TriSalus's technology with Geo-Med's procurement capabilities may serve as a model for similar partnerships in the healthcare sector, ultimately benefiting patients across the nation.